Skip to main content
Erschienen in: Heart and Vessels 3/2011

01.05.2011 | Original Article

Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects

verfasst von: Tsuyoshi Shiga, Takanori Tanaka, Shin Irie, Nobuhisa Hagiwara, Hiroshi Kasanuki

Erschienen in: Heart and Vessels | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of this phase I, dose-escalating study was to evaluate the pharmacokinetics, electrocardiographic effect and safety of amiodarone after a single intravenous administration in Japanese subjects. Thirty-two healthy Japanese male volunteers (20–32 years) were randomized to three single-dose groups (1.25, 2.5 and 5.0 mg/kg). In each group, six (1.25 mg/kg) or ten (2.5 and 5.0 mg/kg) subjects received a single 15-min infusion of intravenous amiodarone, and two subjects received glucose solution as control. The pharmacokinetic profile, blood pressure and electrocardiographic analyses were obtained on a timely basis after up to 77 days. The maximum plasma concentration (C max) and area under the concentration-time curve (AUC0–96) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C max was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC0-96 was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively. A long serum half-life (>14 days) was observed for amiodarone and desethylamiodarone. PR intervals were prolonged at 15 min (0.16 ± 0.0.1 vs. 0.15 ± 0.01 s, p = 0.03) and 18 min (0.17 ± 0.01 vs. 0.15 ± 0.01 s, p = 0.03) with the 5.0 mg/kg dose compared with baseline. No other significant changes in electrocardiographic parameters, pulse rate or blood pressure were observed. A needle-pain-induced vasovagal effect appeared in a volunteer, and three volunteers experienced pain at the drug infusion site. After a single infusion of amiodarone at doses of 1.25–5.0 mg/kg, serum concentrations increased in a dose-dependent manner. A single intravenous amiodarone dose barely affected the electrocardiographic parameters and was well tolerated.
Literatur
1.
Zurück zum Zitat Podrid PJ (1995) Amiodarone: reevaluation of an old drug. Ann Intern Med 122:689–700PubMed Podrid PJ (1995) Amiodarone: reevaluation of an old drug. Ann Intern Med 122:689–700PubMed
2.
Zurück zum Zitat Shiga T, Wakaumi M, Imai T, Suzuki T, Hosaka F, Yamada Y, Matsuda N, Shoda M, Sugiura R, Hagiwara N, Kasanuki H (2002) Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 66:600–604PubMedCrossRef Shiga T, Wakaumi M, Imai T, Suzuki T, Hosaka F, Yamada Y, Matsuda N, Shoda M, Sugiura R, Hagiwara N, Kasanuki H (2002) Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 66:600–604PubMedCrossRef
3.
Zurück zum Zitat Shiga T, Wakaumi M, Matsuda N, Shoda M, Hagiwara N, Sato K, Kasanuki H (2001) Amiodarone-induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan. Jpn Circ J 65:958–960PubMedCrossRef Shiga T, Wakaumi M, Matsuda N, Shoda M, Hagiwara N, Sato K, Kasanuki H (2001) Amiodarone-induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan. Jpn Circ J 65:958–960PubMedCrossRef
4.
Zurück zum Zitat Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H (2007) Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 71:1610–1616PubMedCrossRef Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H (2007) Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 71:1610–1616PubMedCrossRef
5.
Zurück zum Zitat Suzuki S, Yamashita T, Otsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Yamazaki T, Aizawa T (2009) Treatment strategy and clinical outcomes in Japanese patients with atrial fibrillation. Heart Vessels 24:287–293PubMedCrossRef Suzuki S, Yamashita T, Otsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Yamazaki T, Aizawa T (2009) Treatment strategy and clinical outcomes in Japanese patients with atrial fibrillation. Heart Vessels 24:287–293PubMedCrossRef
6.
Zurück zum Zitat Takahashi A, Shiga T, Shoda M, Tanizaki K, Manaka T, Ejima K, Kasanuki H, Hagiwara N (2010) Gender difference in arrhythmic occurrences in patients with nonischemic dilated cardiomyopathy and implantable cardioverter-defibrillator. Heart Vessels 25:150–154PubMedCrossRef Takahashi A, Shiga T, Shoda M, Tanizaki K, Manaka T, Ejima K, Kasanuki H, Hagiwara N (2010) Gender difference in arrhythmic occurrences in patients with nonischemic dilated cardiomyopathy and implantable cardioverter-defibrillator. Heart Vessels 25:150–154PubMedCrossRef
7.
Zurück zum Zitat Chow MS (1996) Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 30:637–643PubMed Chow MS (1996) Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 30:637–643PubMed
8.
Zurück zum Zitat Vadiei K, Troy S, Korth-Bradley J, Chiang ST, Zimmerman JJ (1997) Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol 37:610–617PubMed Vadiei K, Troy S, Korth-Bradley J, Chiang ST, Zimmerman JJ (1997) Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol 37:610–617PubMed
9.
Zurück zum Zitat Roden DM (1993) Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 72:45F–50FPubMedCrossRef Roden DM (1993) Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 72:45F–50FPubMedCrossRef
10.
Zurück zum Zitat Vadiei K, O’Rangers EA, Klamerus KJ, Kluger J, Kazierad DJ, Leese PT, Chow MS, Zimmerman JJ (1996) Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J Clin Pharmacol 36:720–727PubMed Vadiei K, O’Rangers EA, Klamerus KJ, Kluger J, Kazierad DJ, Leese PT, Chow MS, Zimmerman JJ (1996) Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J Clin Pharmacol 36:720–727PubMed
11.
Zurück zum Zitat Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I (2001) Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 103:1317–1324PubMed Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I (2001) Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 103:1317–1324PubMed
12.
Zurück zum Zitat Kodama I, Kamiya K, Toyama J (1999) Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 84:20R–28RPubMedCrossRef Kodama I, Kamiya K, Toyama J (1999) Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 84:20R–28RPubMedCrossRef
13.
Zurück zum Zitat Ikeda N, Nademanee K, Kannan R, Singh BN (1984) Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue concentrations. Am Heart J 108:890–898PubMedCrossRef Ikeda N, Nademanee K, Kannan R, Singh BN (1984) Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue concentrations. Am Heart J 108:890–898PubMedCrossRef
14.
Zurück zum Zitat Desai AD, Chun S, Sung RJ (1997) The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 127:294–303PubMed Desai AD, Chun S, Sung RJ (1997) The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 127:294–303PubMed
15.
Zurück zum Zitat Morady F, DiCarlo LA Jr, Krol RB, Baerman JM, de Buitleir M (1986) Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 7:148–157PubMedCrossRef Morady F, DiCarlo LA Jr, Krol RB, Baerman JM, de Buitleir M (1986) Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 7:148–157PubMedCrossRef
16.
Zurück zum Zitat Cinelli P, Romano S, Castaldo G, de Scalzi M, Citi S, de Leonardis V (1984) Computerized M-mode echocardiography in the assessment of cardiovascular effects during intravenous administration of amiodarone. Methods Find Exp Clin Pharamcol 6:27–32 Cinelli P, Romano S, Castaldo G, de Scalzi M, Citi S, de Leonardis V (1984) Computerized M-mode echocardiography in the assessment of cardiovascular effects during intravenous administration of amiodarone. Methods Find Exp Clin Pharamcol 6:27–32
17.
Zurück zum Zitat Munoz A, Karila P, Gallay P, Zettelmeier F, Messner P, Mery M, Grolleau R (1988) A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 9:142–148PubMed Munoz A, Karila P, Gallay P, Zettelmeier F, Messner P, Mery M, Grolleau R (1988) A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 9:142–148PubMed
18.
Zurück zum Zitat Remme WJ, Kruyssen HA, Look MP, van Hoogenhuyze DC, Krauss XH (1991) Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J 122(1 Pt 1):96–103 Remme WJ, Kruyssen HA, Look MP, van Hoogenhuyze DC, Krauss XH (1991) Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J 122(1 Pt 1):96–103
19.
Zurück zum Zitat Cushing DJ, Adams MP, Cooper WD, Zhang B, Lipicky RJ, Kowey PR (2009) Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol 104:1152–1157PubMedCrossRef Cushing DJ, Adams MP, Cooper WD, Zhang B, Lipicky RJ, Kowey PR (2009) Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol 104:1152–1157PubMedCrossRef
20.
Zurück zum Zitat Kowey PR, Marinchak RA, Rials SJ, Filart RA (1997) Intravenous amiodarone. J Am Coll Cardiol 29:1190–1198PubMedCrossRef Kowey PR, Marinchak RA, Rials SJ, Filart RA (1997) Intravenous amiodarone. J Am Coll Cardiol 29:1190–1198PubMedCrossRef
Metadaten
Titel
Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects
verfasst von
Tsuyoshi Shiga
Takanori Tanaka
Shin Irie
Nobuhisa Hagiwara
Hiroshi Kasanuki
Publikationsdatum
01.05.2011
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 3/2011
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-010-0047-7

Weitere Artikel der Ausgabe 3/2011

Heart and Vessels 3/2011 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.